Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury

Next Previous
Trial Profile

A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Spinal cord injuries
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Pathway
  • Sponsors StemCells

Most Recent Events

  • 31 May 2016 According to a StemCells Inc. media release, the Interim Analysis Data Monitoring Committee concluded that the data failed the futility criteria established for the interim analysis and recommended cessation of the study.
  • 31 May 2016 According to a StemCells, Inc. media release, status changed from recruiting to discontinued.
  • 18 Apr 2016 According to a StemCells media release, enrollment of cohort I has been complete and the company is now enrolling patients into cohort II. 19 patients have been enrolled and randomised and the enrollment is expected to be completed by the end of September 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top